# Infiltrating Ductal Breast Carcinoma in a Male Patient With Associated BARD1 Mutation

## TL;DR

A rare case of male breast cancer with a BARD1 gene mutation is presented, highlighting the importance of genetic testing in diagnosis and treatment.

## Contribution

This case report adds to the limited literature on male breast cancer by identifying a BARD1 mutation in a patient.

## Key findings

- The patient had infiltrating ductal carcinoma confirmed by biopsy and imaging.
- Genetic testing revealed MUTYH and BARD1 gene mutations in the tumor tissue.
- The tumor was histopathologically characterized as Grade 2, ER/PR-positive, and HER2-negative.

## Abstract

Male breast cancer is an uncommon diagnosis with limited research on management and prognosis due to its rarity. We discuss a case of a 55-year-old male with a non-contributory past medical history who presented with an enlarging palpable mass of his right breast tissue at the 10:00 position. The ultrasound of the right breast showed a 2.8 cm heterogenous mass with irregular borders highly suspicious for malignancy. The follow-up sonogram-guided core biopsy was performed, and the pathology of the mass confirmed high-grade infiltrating ductal carcinoma. A modified radical mastectomy of the right breast with extensive axillary lymph node excision was performed. Genetic testing of the excised tumor revealed a MUTYH gene mutation and a BARD1 (BRCA1-associated RING domain 1) gene mutation of unknown significance. Histopathological analysis confirmed a Grade 2, ER/PR-positive, KI 67-positive, and HER2-negative tumor.